Table 1.
Summary data from the human ovarian tumours Cohort 1
| Histology | N | Mean age (range) | Median Grade | Median Stage | Surgery (Number of patients) |
Platinum Status (Number of patients) |
Median PFS | Median OS | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Interval | Sensitive | Resistant | |||||||
| Pelvic serous carcinoma | 75 | 65.28 (40–86) | 3 | 3 | 22 | 53 | 56 | 17 | 10 | 31 |
| Serous adenocarcinoma | 58 | 65.60 (42–86) | 3 | 3 | 20 | 38 | 43 | 14 | 10 | 32 |
| Primary peritoneal adenocarcinoma | 17 | 64.47 (40–74) | 3 | 3 | 2 | 15 | 13 | 3 | 10 | 34 |
| Endometrioid adenocarcinoma | 8 | 61.63 (45–84) | 3 | 3 | 7 | 1 | 5 | 2 | 11 | 30.5 |
| Mucinous adenocarcinoma | 2 | 54 (48–60) | 3 | 3 | 1 | 1 | 0 | 1 | 1 | 6.5 |
| Clear cell carcinoma | 4 | 49(40–62) | 3 | 3 | 4 | 0 | 1 | 2 | 1 | 14 |
| MMMT | 6 | 72.50 (62–90) | 3 | 3 | 5 | 1 | 0 | 3 | 1.5 | 5 |
| Borderline epithelial tumour | 8 | 56 (36–69) | – | – | 8 | 0 | – | – | – | – |
| Benign tumour | 5 | 55.2 (48–68) | – | – | – | – | – | – | – | – |
| Normal ovary | 5 | 67.58 (54–84) | – | – | – | – | – | – | – | – |